Why Patients Switch From Compounded to Commercial
The three most common reasons patients transition from compounded to brand-name GLP-1s: insurance coverage kicks in (employer plan adds coverage, Medicare Bridge enrollment, or a successful prior authorization), a desire for FDA-approved consistency after stabilizing on compounded, or the compounded supply becomes unreliable due to regulatory changes affecting compounding pharmacies.
Whatever the reason, the transition requires clinical coordination to ensure dose equivalence and avoid treatment disruption.
Dose Equivalence: Semaglutide
| Compounded Semaglutide Dose | Equivalent Wegovy Dose | Notes |
|---|---|---|
| 0.25 mg/week | 0.25 mg pen | Direct 1:1 |
| 0.5 mg/week | 0.5 mg pen | Direct 1:1 |
| 1.0 mg/week | 1.0 mg pen | Direct 1:1 |
| 1.7 mg/week | 1.7 mg pen | Direct 1:1 |
| 2.4 mg/week | 2.4 mg pen | Direct 1:1 |
| Non-standard dose (e.g., 1.25 mg) | Nearest available (1.0 or 1.7 mg) | Prescriber judgment |
For injectable semaglutide, the conversion is straightforward because the molecule and route are the same. The difference is in manufacturing standards: Wegovy pens are manufactured by Novo Nordisk under FDA oversight, while compounded vials come from 503A or 503B pharmacies under different regulatory frameworks. The clinical effect should be equivalent at the same dose.
Sesame Care
Brand-Name Marketplace
From $99/visit
FDA-approved brand-name medications only (Wegovy, Zepbound, Foundayo). Not compounded.
Paid link Check Eligibility →Dose Equivalence: Tirzepatide
Converting from compounded tirzepatide to brand-name Zepbound follows the same milligram-to-milligram logic. Zepbound KwikPens are available in 2.5, 5, 7.5, 10, 12.5, and 15 mg doses. Match your compounded dose to the nearest available pen strength.
For patients on compounded doses between standard increments (e.g., 3.75 mg), your prescriber will round to the nearest available commercial dose — typically rounding down for safety and adjusting based on your response.
Insurance Documentation for the Switch
When transitioning from compounded to brand-name, your insurance company doesn't care about your compounded treatment history — they evaluate the brand-name prescription on its own merits. However, your treatment history can support the PA submission: documented response to semaglutide or tirzepatide (even compounded versions) demonstrates that you respond to the medication, which strengthens the medical necessity argument.
Have your prescriber include in the PA: your starting BMI and current BMI, the weight loss achieved on compounded GLP-1 therapy, current dose level and tolerance, and any comorbidity improvements (A1C, blood pressure, lipids). This creates a compelling case for continued treatment with the brand-name product.
Embody
Top Pick — $400 CPA
From $249/mo
Injectable semaglutide only. Compounded — not FDA-approved.
Paid link Check Eligibility →Wellorithm
Science-Forward
From $199/mo
Compounded — not FDA-approved.
Paid link Check Eligibility →